206 related articles for article (PubMed ID: 26951320)
1. Is Estradiol Monitoring Necessary in Women Receiving Ovarian Suppression for Breast Cancer?
Papakonstantinou A; Foukakis T; Rodriguez-Wallberg KA; Bergh J
J Clin Oncol; 2016 May; 34(14):1573-9. PubMed ID: 26951320
[TBL] [Abstract][Full Text] [Related]
2. Maximizing the Clinical Benefit of Anthracyclines in Addition to Taxanes in the Adjuvant Treatment of Early Breast Cancer.
Curigliano G; Criscitiello C
J Clin Oncol; 2017 Aug; 35(23):2600-2603. PubMed ID: 28661760
[TBL] [Abstract][Full Text] [Related]
3. Breast Reconstruction With Postmastectomy Radiation: Choices and Tradeoffs.
Poppe MM; Agarwal JP
J Clin Oncol; 2017 Aug; 35(22):2467-2470. PubMed ID: 28481705
[TBL] [Abstract][Full Text] [Related]
4. Assessment of ovarian function after chemotherapy in women with early and locally advanced breast cancer from Serbia.
Malisic E; Susnjar S; Milovanovic J; Todorovic-Rakovic N; Kesic V
Arch Gynecol Obstet; 2018 Feb; 297(2):495-503. PubMed ID: 29101609
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII.
Bernhard J; Zahrieh D; Castiglione-Gertsch M; Hürny C; Gelber RD; Forbes JF; Murray E; Collins J; Aebi S; Thürlimann B; Price KN; Goldhirsch A; Coates AS;
J Clin Oncol; 2007 Jan; 25(3):263-70. PubMed ID: 17159194
[TBL] [Abstract][Full Text] [Related]
6. Blocking the Cycle: Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic, Hormone Receptor-Positive Breast Cancer.
Wander SA; Mayer EL; Burstein HJ
J Clin Oncol; 2017 Sep; 35(25):2866-2870. PubMed ID: 28580881
[TBL] [Abstract][Full Text] [Related]
7. [Adjuvant chemotherapy of premenopausal breast cancer with LH-RH analogue for ovarian protection--a case report].
Asaga S; Ando J; Arai T; Fujii H
Gan To Kagaku Ryoho; 2005 Jul; 32(7):1069-72. PubMed ID: 16044976
[TBL] [Abstract][Full Text] [Related]
8. Goserelin plus tamoxifen compared to chemotherapy followed by tamoxifen in premenopausal patients with early stage-, lymph node-negative breast cancer of luminal A subtype.
Alramadhan M; Ryu JM; Rayzah M; Nam SJ; Kim SW; Yu J; Lee SK; Bae SY; Park S; Paik HJ; Lee JE
Breast; 2016 Dec; 30():111-117. PubMed ID: 27697675
[TBL] [Abstract][Full Text] [Related]
9. Improving Adjuvant Endocrine Treatment Tailoring in Premenopausal Women With Hormone Receptor-Positive Breast Cancer.
Lambertini M; Blondeaux E; Perrone F; Del Mastro L
J Clin Oncol; 2020 Apr; 38(12):1258-1267. PubMed ID: 31618128
[No Abstract] [Full Text] [Related]
10. Impact on disease-free survival of the duration of ovarian function suppression, as postoperative adjuvant therapy, in premenopausal women with hormone receptor-positive breast cancer: a retrospective single-institution study.
Ozaki Y; Tanabe Y; Tamura N; Ogura T; Kondoh C; Miura Y; Yoshimura K; Kawabata H; Takano T
Breast Cancer; 2018 May; 25(3):343-349. PubMed ID: 29357022
[TBL] [Abstract][Full Text] [Related]
11. Health-related quality of life in early breast cancer.
Groenvold M
Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
[TBL] [Abstract][Full Text] [Related]
12. Use of goserelin in the treatment of breast cancer.
Rody A; Loibl S; von Minckwitz G; Kaufmann M
Expert Rev Anticancer Ther; 2005 Aug; 5(4):591-604. PubMed ID: 16111461
[TBL] [Abstract][Full Text] [Related]
13. Lymphedema Precautions: Time to Abandon Old Practices?
Ahn S; Port ER
J Clin Oncol; 2016 Mar; 34(7):655-8. PubMed ID: 26712226
[TBL] [Abstract][Full Text] [Related]
14. Left Ventricular Dysfunction With Trastuzumab Therapy: Is Primary Prevention the Best Option?
Thavendiranathan P; Amir E
J Clin Oncol; 2017 Mar; 35(8):820-825. PubMed ID: 28029315
[TBL] [Abstract][Full Text] [Related]
15. [A case of premenopausal stage IV breast cancer responding to neoadjuvant endocrine therapy after chemotherapy with FEC].
Konishi K; Hasegawa N; Kaneko H; Iimura Y; Shoji Y; Kawabata M
Gan To Kagaku Ryoho; 2010 Jan; 37(1):111-3. PubMed ID: 20087042
[TBL] [Abstract][Full Text] [Related]
16. Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer.
Jankowitz RC; McGuire KP; Davidson NE
Breast; 2013 Aug; 22 Suppl 2():S165-70. PubMed ID: 24074781
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women.
Carlson RW; Theriault R; Schurman CM; Rivera E; Chung CT; Phan SC; Arun B; Dice K; Chiv VY; Green M; Valero V
J Clin Oncol; 2010 Sep; 28(25):3917-21. PubMed ID: 20679610
[TBL] [Abstract][Full Text] [Related]
18. Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials.
Bernhard J; Luo W; Ribi K; Colleoni M; Burstein HJ; Tondini C; Pinotti G; Spazzapan S; Ruhstaller T; Puglisi F; Pavesi L; Parmar V; Regan MM; Pagani O; Fleming GF; Francis PA; Price KN; Coates AS; Gelber RD; Goldhirsch A; Walley BA
Lancet Oncol; 2015 Jul; 16(7):848-58. PubMed ID: 26092816
[TBL] [Abstract][Full Text] [Related]
19. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188).
Davidson NE; O'Neill AM; Vukov AM; Osborne CK; Martino S; White DR; Abeloff MD
J Clin Oncol; 2005 Sep; 23(25):5973-82. PubMed ID: 16087950
[TBL] [Abstract][Full Text] [Related]
20. Ovarian Function Suppression in Premenopausal Women With Concurrent Endocrine Therapy Use.
Fleege NMG; Li Y; Kidwell KM; Henry NL
Clin Breast Cancer; 2023 Jun; 23(4):454-460. PubMed ID: 37076363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
